HomeComparePETFF vs ABBV

PETFF vs ABBV: Dividend Comparison 2026

PETFF yields 12.91% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PETFF wins by $414.27M in total portfolio value
10 years
PETFF
PETFF
● Live price
12.91%
Share price
$0.55
Annual div
$0.07
5Y div CAGR
62.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$414.38M
Annual income
$371,149,854.13
Full PETFF calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — PETFF vs ABBV

📍 PETFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPETFFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PETFF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PETFF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PETFF
Annual income on $10K today (after 15% tax)
$1,097.69/yr
After 10yr DRIP, annual income (after tax)
$315,477,376.01/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, PETFF beats the other by $315,455,509.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PETFF + ABBV for your $10,000?

PETFF: 50%ABBV: 50%
100% ABBV50/50100% PETFF
Portfolio after 10yr
$207.24M
Annual income
$185,587,789.93/yr
Blended yield
89.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PETFF
No analyst data
Altman Z
1.8
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PETFF buys
0
ABBV buys
0
No recent congressional trades found for PETFF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPETFFABBV
Forward yield12.91%3.12%
Annual dividend / share$0.07$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR62.8%40.6%
Portfolio after 10y$414.38M$104.7K
Annual income after 10y$371,149,854.13$25,725.73
Total dividends collected$411.03M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PETFF vs ABBV ($10,000, DRIP)

YearPETFF PortfolioPETFF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$12,802$2,102.40$11,559$438.51+$1.2KPETFF
2$17,794$4,095.22$13,494$640.86+$4.3KPETFF
3$27,699$8,660.13$15,951$945.97+$11.7KPETFF
4$50,150$20,511.55$19,152$1,413.89+$31.0KPETFF
5$110,163$56,502.60$23,443$2,146.38+$86.7KPETFF
6$306,719$188,844.48$29,391$3,321.96+$277.3KPETFF
7$1,128,170$799,980.56$37,948$5,265.87+$1.09MPETFF
8$5,684,109$4,476,966.93$50,795$8,596.74+$5.63MPETFF
9$40,401,609$34,319,612.98$71,034$14,549.41+$40.33MPETFF
10$414,379,576$371,149,854.13$104,715$25,725.73+$414.27MPETFF

PETFF vs ABBV: Complete Analysis 2026

PETFFStock

PTT Public Company Limited, together with its subsidiaries, operates as a petroleum and petrochemical company in Thailand, other Asian countries, Europe, the United States, and internationally. It operates through Upstream Petroleum and Natural Gas Business Group, Downstream Petroleum Business Group, and New Business and Infrastructure Group. The company is involved in the exploration and production of petroleum; and natural gas procurement, pipeline transmission, distribution, and separation activities. In addition, it engages in the exploration, production, and distribution of coal; and marketing of petroleum products and lube oil through an operating system of procurement, storage, and distribution of products, as well as the retail business at service stations. Further, the company imports and exports petroleum and petrochemical products, as well as other related products; produces and distributes electricity, steam, and water for industrial purpose; and offers project management, human resource support, petroleum related technology, consultant management, technical consultant for electricity businesses, petrol station and convenience store management, factory maintenance and engineering, oil and gas, safety and environmental, and business services, as well as services for the storage and handling of liquid chemicals. Additionally, it invests in liquefied natural gas business; produces and distributes chilled water/constructs and installs electricity generating systems; develops electricity power production projects; develops, markets, and distributes polymers products, by products, and other polymers-related products; develops real estate properties; operates vocational schools; and manufactures and distributes biochemical products, paraxylene, and industrial coatings and additives, as well as engages in the transportation, warehouse, and bagging packing management of polyethylene. The company was founded in 1978 and is headquartered in Bangkok, Thailand.

Full PETFF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PETFF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PETFF vs SCHDPETFF vs JEPIPETFF vs OPETFF vs KOPETFF vs MAINPETFF vs JNJPETFF vs MRKPETFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.